https://www.neuroem....technology/#196
NeuroEM’s just-completed clinical trial is the first to administer TEMT to the entire human brain, and over an extended period of time. This open-label study was designed to evaluate the safety and initial clinical efficacy of TEMT against AD. Eight mild/moderate AD patients were treated with TEMT in-home by their caregivers for two months utilizing NeuroEM’s MemorEM™ head device.
They are saying it may become available in 2021 or so as follows.
It is anticipated that, with adequate funding and adherence to our clinical timeline, our MemorEM™ head device for treating AD could be available for commercialization in late 2021 or early 2022.
I would like to buy it for my father who has been having memory issues.
Edited by ryukenden, 01 October 2019 - 11:32 PM.